Homology Modeling and Molecular Dynamics Simulations of Trypanosoma cruzi Phosphodiesterase b1
- PMID: 34813143
- DOI: 10.1002/cbdv.202100712
Homology Modeling and Molecular Dynamics Simulations of Trypanosoma cruzi Phosphodiesterase b1
Abstract
Cyclic nucleotide phosphodiesterases have been implicated in the proliferation, differentiation and osmotic regulation of trypanosomatids; in some trypanosomatid species, they have been validated as molecular targets for the development of new therapeutic agents. Because the experimental structure of Trypanosoma cruzi PDEb1 (TcrPDEb1) has not been solved so far, an homology model of the target was created using the structure of Trypanosoma brucei PDEb1 (TbrPDEb1) as a template. The model was refined by extensive enhanced sampling molecular dynamics simulations, and representative snapshots were extracted from the trajectory by combined clustering analysis. This structural ensemble was used to develop a structure-based docking model of the target. The docking accuracy of the model was validated by redocking and cross-docking experiments using all available crystal structures of TbrPDEb1, whereas the scoring accuracy was validated through a retrospective screen, using a carefully curated dataset of compounds assayed against TbrPDEb1 and/or TcrPDEb1. Considering the results from in silico validations, the model may be applied in prospective virtual screening campaigns to identify novel hits, as well as to guide the rational design of potent and selective inhibitors targeting this enzyme.
Keywords: Chagas disease; Trypanosoma cruzi; homology modeling; molecular docking; molecular dynamics; phosphodiesterase.
© 2021 Wiley-VHCA AG, Zurich, Switzerland.
References
-
- K. C. F. Lidani, F. A. Andrade, L. Bavia, F. S. Damasceno, M. H. Beltrame, I. J. Messias-Reason, T. L. Sandri, ‘Chagas Disease: From Discovery to a Worldwide Health Problem’, Front. Public Health 2019, 7, 166.
-
- C. A. Morillo, J. A. Marin-Neto, A. Avezum, S. Sosa-Estani, A. Rassi, F. Rosas, E. Villena, R. Quiroz, R. Bonilla, C. Britto, F. Guhl, E. Velazquez, L. Bonilla, B. Meeks, P. Rao-Melacini, J. Pogue, A. Mattos, J. Lazdins, A. Rassi, S. J. Connolly, S. Yusuf, ‘Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy’, N. Engl. J. Med. 2015, 373, 1295-1306.
-
- M. Vallejo, P. P. Reyes, M. M. Garcia, A. G. G. Garay, ‘Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection)’, Cochrane Database Syst. Rev. 2020, DOI 10.1002/14651858.CD004102.pub3.
-
- G. D. Alonso, A. C. Schoijet, H. N. Torres, M. M. Flawiá, ‘TcrPDEA1, a cAMP-specific phosphodiesterase with atypical pharmacological properties from Trypanosoma cruzi’, Mol. Biochem. Parasitol. 2007, 152, 72-79.
-
- Y. Shakur, H. P. de Koning, H. Ke, J. Kambayashi, T. Seebeck, ‘Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases’, Handb. Exp. Pharmacol. 2011, 487-510.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources